본문 바로가기
KERD
논문KCI 등재

Consensus Guidelines for the Treatment of Atopic Dermatitis in Korea (Part II): Systemic Treatment

이경호|김현정|서영준|최응호|서성준|이승철|장용현|홍승필|조상현|이양원|노주영|박귀영|배정민|유박린|손상욱|김정은|서기범|고현창|박영립|박천욱
대한피부과학회 (Korean Dermalogical Association)|2015.10|Annals of Dermatology|제27권 제5호|pp. 578-592

1

조회

0

다운로드

17

인용

0

참고문헌

키워드

KoreaGuidelineoralDermatitisAdministrationTherapeutics
주제분류피부과학

초록

Background: Since the treatment guidelines for atopic dermatitis (AD) were issued by the Korean Atopic Dermatitis Association (KADA) work group in 2006, there have been further advances in the systemic treatment of AD. Objective: We aimed to establish updated evidence- and experience- based systemic treatment guidelines for Korean AD. Methods: We compiled a database of references from relevant systematic reviews and guidelines regarding the systemic management of AD, including antihistamines, antimicrobials, systemic immunomodulators, allergen-specific immunotherapy, phototherapy, adjunctive treatment, and complementary and alternative medicines. Evidence for each statement was graded and classified based on the strength of the recommendation. Thirty-nine council members of KADA participated in the three rounds of votes and expert consensus recommendations were established. Results: The use of antihistamines is recommended to relieve pruritus and to prevent exacerbation due to scratching in AD patients. Infection should be controlled as needed and long-term medication should be avoided. For moderate to severe AD patients, concomitant active treatments with systemic immunomodulators are indicated. Cyclosporine is the first choice among systemic immunomodulators and others should be considered as second-line alternatives. Allergen- specific immunotherapy could be effective in AD patients with aeroallergen hypersensitivity. Phototherapy can be useful for moderate to severe AD patients and narrowband ultraviolet B is the most effective option. Complementary and alternative medicines cannot be recommended for treating AD. Conclusion: We expect these recommendations to be a reference guide for physicians and AD patients in choosing the appropriate treatment to improve quality of life and decrease unnecessary social medical costs.

Abstract

Background: Since the treatment guidelines for atopic dermatitis (AD) were issued by the Korean Atopic Dermatitis Association (KADA) work group in 2006, there have been further advances in the systemic treatment of AD. Objective: We aimed to establish updated evidence- and experience- based systemic treatment guidelines for Korean AD. Methods: We compiled a database of references from relevant systematic reviews and guidelines regarding the systemic management of AD, including antihistamines, antimicrobials, systemic immunomodulators, allergen-specific immunotherapy, phototherapy, adjunctive treatment, and complementary and alternative medicines. Evidence for each statement was graded and classified based on the strength of the recommendation. Thirty-nine council members of KADA participated in the three rounds of votes and expert consensus recommendations were established. Results: The use of antihistamines is recommended to relieve pruritus and to prevent exacerbation due to scratching in AD patients. Infection should be controlled as needed and long-term medication should be avoided. For moderate to severe AD patients, concomitant active treatments with systemic immunomodulators are indicated. Cyclosporine is the first choice among systemic immunomodulators and others should be considered as second-line alternatives. Allergen- specific immunotherapy could be effective in AD patients with aeroallergen hypersensitivity. Phototherapy can be useful for moderate to severe AD patients and narrowband ultraviolet B is the most effective option. Complementary and alternative medicines cannot be recommended for treating AD. Conclusion: We expect these recommendations to be a reference guide for physicians and AD patients in choosing the appropriate treatment to improve quality of life and decrease unnecessary social medical costs.

참고문헌 (79)

  1. Kim SY, "Guidance for development of clinical practice guidelines", National Evidence-Based Healthcare Collaborating Agency, 607~608 (2011)
  2. "Oxford Centre for Evidence-based Medicine-Levels of evidence" (2009)[URL]
  3. Sidbury R, "Guidelines of care for the management of atopic dermatitis:section 3. Management and treatment with phototherapy and systemic agents", J Am Acad Dermatol, 71, pp.327~349 (2014), American Academy of Dermatology
  4. Kawashima M, "Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebocontrolled, parallel-group study", Br J Dermatol, 148, pp.1212~1221 (2003)
  5. Ring J, "Guidelines for treatment of atopic eczema (atopic dermatitis) part I", J Eur Acad Dermatol Venereol, 26, pp.1045~1060 (2012)
  6. Diepgen TL, "Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months", Pediatr Allergy Immunol, 13, pp.278~286 (2002)
  7. Langeland T, "Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis. A multi-crossover-designed study", Allergy, 49, pp.22~26 (1994)
  8. La Rosa M, "Double-blind study of cetirizine in atopic eczema in children", Ann Allergy, 73, pp.117~122 (1994)
  9. Wahlgren CF, "The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis", Br J Dermatol, 122, pp.545~551 (1990)
  10. Boguniewicz M, "Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis", J Allergy Clin Immunol, 108, pp.651~652 (2001)
  11. Bath-Hextall FJ, "Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review", Br J Dermatol, 163, pp.12~26 (2010)
  12. Eichenfield LF, "Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies", J Am Acad Dermatol, 71, pp.116~132 (2014)
  13. Wollenberg A, "factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases", J Am Acad Dermatol, 49, pp.198~205 (2003)
  14. Lübbe J, "Secondary infections in patients with atopic dermatitis", Am J Clin Dermatol, 4, pp.641~654 (2003)
  15. Lintu P, "Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts", Allergy, 56, pp.512~517 (2001)
  16. Mayser P, "Treatment of head and neck dermatitis with ciclopiroxolamine cream--results of a double-blind, placebocontrolled study", Skin Pharmacol Physiol, 19, pp.153~158 (2006)
  17. Flohr C, "Systemic therapies for severe atopic dermatitis in children and adults", J Allergy Clin Immunol, 132, pp.774~ (2013)
  18. Haeck IM, "Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial", J Am Acad Dermatol, 64, pp.1074~1084 (2011)
  19. Roekevisch E, "Efficacy and safety of systemic treatments for moderateto-severe atopic dermatitis: a systematic review", J Allergy Clin Immunol, 133, pp.429~438 (2014)
  20. Berth-Jones J, "Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis", Br J Dermatol, 136, pp.76~81 (1997)
  21. Forte WC, "Rebound phenomenon to systemic corticosteroid in atopic dermatitis", Allergol Immunopathol (Madr), 33, pp.307~311 (2005)
  22. Garnacho-Saucedo G, "Atopic dermatitis: update and proposed management algorithm", Actas Dermosifiliogr, 104, pp.4~16 (2013)
  23. Rubel D, "Asia-Pacific Consensus Group for Atopic Dermatitis. Consensus guidelines for the management of atopic dermatitis: an Asia-Pacific perspective", J Dermatol, 40, pp.160~171 (2013)
  24. Schmitt J, "Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial", Br J Dermatol, 162, pp.661~668 (2010)
  25. Daley-Yates PT, "Relationship between systemic corticosteroid exposure and growth velocity:development and validation of a pharmacokinetic", pharmacodynamic model, 2004, pp.26, 1905~1919
  26. Czech W, "A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life", J Am Acad Dermatol, 42, pp.653~659 (2000)
  27. El-Khalawany MA, "Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt", Eur J Pediatr, 172, pp.351~356 (2013)
  28. Hoare C, "Systematic review of treatments for atopic eczema", Health Technol Assess, 4, pp.1~191 (2000)
  29. Berth-Jones J, "Cyclosporine in severe childhood atopic dermatitis: a multicenter study", J Am Acad Dermatol, 34, pp.1016~1021 (1996)
  30. Zurbriggen B, "Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis. Aa double-blind, single-centre, cross-over pilot study", Dermatology, 198, pp.56~60 (1999)
  31. Berth-Jones J, "Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial", Br J Dermatol, 147, pp.324~330 (2002)
  32. Schram ME, "A randomized trial of methotrexate versus azathioprine for severe atopic eczema", J Allergy Clin Immunol, 128, pp.353~359 (2011)
  33. Schmedt N, "Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS)", Pharmacoepidemiol Drug Saf, 21, pp.1216~1220 (2012)
  34. Meggitt SJ, "Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial", Lancet, 367, pp.839~846 (2006)
  35. Caufield M, "Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring", J Am Acad Dermatol, 68, pp.29~35 (2013)
  36. Ballester I, "Severe adult atopic dermatitis: treatment with mycophenolate mofetil in 8 patients", Actas Dermosifiliogr, 100, pp.883~887 (2009)
  37. Heller M, "Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients", Br J Dermatol, 157, pp.127~132 (2007)
  38. Bae JM, "Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials", J Allergy Clin Immunol, 132, pp.110~117 (2013)
  39. Cox L, "Allergen immunotherapy: a practice parameter third update", J Allergy Clin Immunol, 127(1 Suppl), pp.S1~S55 (2011)
  40. Burks AW, "Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology", European Academy of Allergy and Clinical Immunology, J Allergy Clin Immunol, pp.2013, 131[DOI]
  41. Bussmann C, "Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis?", J Allergy Clin Immunol, 118, pp.1292~1298 (2006)
  42. Bussmann C, "Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study", Clin Exp Allergy, 37, pp.1277~1285 (2007)
  43. Werfel T, "Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study", Allergy, 61, pp.202~205 (2006)
  44. Novak N, "Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis", J Allergy Clin Immunol, 130, pp.925.e4~931.e4 (2012)
  45. Pajno GB, "Sublingual immunotherapy in mitesensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study", J Allergy Clin Immunol, 120, pp.164~170 (2007)
  46. Garritsen FM, "Photo(chemo)therapy in the management of atopic dermatitis:an updated systematic review with implications for practice and research", Br J Dermatol, 170, pp.501~513 (2014)
  47. Meduri NB, "Phototherapy in the management of atopic dermatitis: a systematic review", Photodermatol Photoimmunol Photomed, 23, pp.106~112 (2007)
  48. Tintle S, "Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response", J Allergy Clin Immunol, 128, pp.583~593 (2011)
  49. Grundmann SA, "Modern aspects of phototherapy for atopic dermatitis", J Allergy (Cairo), 2012, pp.21797~ (2012)
  50. 서기석, "Efficacy of Ultraviolet A1 Phototherapy in Recalcitrant Skin Diseases", Annals of Dermatology, 22(1), pp.1~8 (2010), 대한피부과학회
  51. Tzaneva S, "High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis", J Am Acad Dermatol, 45, pp.503~507 (2001)
  52. Gambichler T, "Medium-dose ultraviolet (UV) A1vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study", Br J Dermatol, 160, pp.652~658 (2009)
  53. Majoie IM, "Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis", J Am Acad Dermatol, 60, pp.77~84 (2009)
  54. Panahi Y, "Recombinant human interferon gamma (Gamma Immunex)in treatment of atopic dermatitis", Clin Exp Med, 12, pp.241~245 (2012)
  55. Hanifin JM, "Recombinant interferon gamma therapy for atopic dermatitis", J Am Acad Dermatol, 28, pp.189~197 (1993)
  56. D'Erme AM, "Efficacy of treatment with oral alitretinoin in patient suffering from lichen simplex chronicus and severe atopic dermatitis of hands", Dermatol Ther, 27, pp.21~23 (2014)
  57. Stiller MJ, "A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis", J Am Acad Dermatol, 30, pp.597~602 (1994)
  58. Taïeb A, "Biologics in atopic dermatitis", J Dtsch Dermatol Ges, 10, pp.174~178 (2012)
  59. Kim DH, "Antiimmunoglobulin E in the treatment of refractory atopic dermatitis", Clin Exp Dermatol, 38, pp.496~500 (2013)
  60. Simon D, "Anti-CD20 (rituximab) treatment improves atopic eczema", J Allergy Clin Immunol, 121, pp.122~128 (2008)
  61. Moul DK, "Alefacept for moderate to severe atopic dermatitis: a pilot study in adults", J Am Acad Dermatol, 58, pp.984~989 (2008)
  62. Oldhoff JM, "Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis", Allergy, 60, pp.693~696 (2005)
  63. Kim SO, "Effects of probiotics for the treatment of atopic dermatitis: a meta-analysis of randomized controlled trials", Ann Allergy Asthma Immunol, 113, pp.217~226 (2014)
  64. Panduru M, "Probiotics and primary prevention of atopic dermatitis: a meta-analysis of randomized controlled studies", J Eur Acad Dermatol Venereol, 29, pp.232~242 (2015)
  65. Mohajeri S, "Review of evidence for dietary influences on atopic dermatitis", Skin Therapy Lett, 19, pp.5~7 (2014)
  66. Bamford JT, "Oral evening primrose oil and borage oil for eczema", Cochrane Database Syst Rev, 4, pp.CD004416~ (2013)
  67. Morse NL, "A meta-analysis of randomized, placebo-controlled clinical trials of Efamol evening primrose oil in atopic eczema. Where do we go from here in light of more recent discoveries?", Curr Pharm Biotechnol, 7, pp.503~524 (2006)
  68. Camargo CA Jr, "Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children", J Allergy Clin Immunol, 134, pp.831.e1~835.e1 (2014)
  69. Hata TR, "A randomized controlled double-blind investigation of the effects of vitamin D dietary supplementation in subjects with atopic dermatitis", J Eur Acad Dermatol Venereol, 28, pp.781~789 (2014)
  70. Bath-Hextall FJ, "Dietary supplements for established atopic eczema", Cochrane Database Syst Rev, 2, pp.CD005205~ (2012)
  71. Higgins E, "Disseminated parapox (orf) in a 13-year-old boy with atopic dermatitis following acupuncture", Clin Exp Dermatol, 36, pp.809~811 (2011)
  72. Tan HY, "Chinese herbal medicine for atopic dermatitis: a systematic review", J Am Acad Dermatol, 69, pp.295~304 (2013)
  73. Perharic L, "Possible association of liver damage with the use of Chinese herbal medicine for skin disease", Vet Hum Toxicol, 37, pp.562~566 (1995)
  74. Oranje AP, "Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score", Br J Dermatol, 157, pp.645~648 (2007)
  75. Hanifin JM, "The eczema area and severity index (EASI):assessment of reliability in atopic dermatitis. EASI Evaluator Group", Exp Dermatol, 10, pp.11~18 (2001)
  76. Choi WJ, "Prevalence and risk factors for atopic dermatitis: a cross-sectional study of 6,453 Korean preschool children", Acta Derm Venereol, 92, pp.467~471 (2012)
  77. 신지연, "An Educational Program That Contributes to Improved Patient and Parental Understanding of Atopic Dermatitis", Annals of Dermatology, 26(1), pp.66~72 (2014), 대한피부과학회
  78. Research of understanding and social loss of atopic dermatitis in Korea, "Seo SJ", Korean Center for Disease Control and Prevention, ~, pp.Report No.:2010 E 3302600 (2011)
  79. 김정은, "Disease Awareness and Management Behavior of Patients with Atopic Dermatitis: A Questionnaire Survey of 313 Patients", Annals of Dermatology, 27(1), pp.40~47 (2015), 대한피부과학회

관련 논문AI추천

Consensus Update for Systemic Treatment of Atopic Dermatitis김정은, 김혜원, 나찬호, 노주영, 박영립, 박창욱, 배정민, 변지연, 서영준, 손상욱, 신민경, 안지영, 유박린, 이양원, 이지현, 장용현, 최응호, 한태영, 홍승필, Park Gyeong-Hun대한피부과학회 · Annals of Dermatology2021 · 제33권 제6호Consensus-Based Guidelines for the Treatment of Atopic Dermatitis in Korea (Part I): Basic Therapy, Topical Therapy, and Conventional Systemic Therapy고주연, 고현창, 나찬호, 서영준, 신민경, 안지영, 유박린, 이동훈, 이상은, 이설희, 장용현, 전지현, 한태영, Bae Youin, Choi Sun Young, Cho Sang Hyun, Han Ju Hee, Kim Hye One, Lee Ji Hyun, Lee Yang Won, Son Sang Wook, Woo Yu Ri대한피부과학회 · Annals of Dermatology2025 · 제37권 제4호Consensus Guidelines for the Treatment of Atopic Dermatitis in Korea (Part I): General Management and Topical Treatment고현창, 김정은, 김현정, 노주영, 박귀영, 박영립, 박천욱, 배정민, 서기범, 서성준, 서영준, 손상욱, 유박린, 이경호, 이승철, 이양원, 장용현, 조상현, 최응호, 홍승필대한피부과학회 · Annals of Dermatology2015 · 제27권 제5호난치성 아토피피부염 Work Group 보고서: 난치성 아토피피부염의 치료에 관한 전문가 의견서박양, 김규한, 김범준, 김우경, 김정은, 김현희, 남동호, 박준수, 염혜영, 오재원, 이소연, 이애영, 홍수종, 대한천식알레르기학회대한천식알레르기학회 · 천식 및 알레르기2010 · 제30권 제4호Consensus-Based Guidelines for the Treatment of Atopic Dermatitis in Korea (Part II): Biologics and JAK inhibitors고주연, 고현창, 나찬호, 서영준, 손상욱, 신민경, 안지영, 유박린, 이동훈, 이상은, 이설희, 장용현, 전지현, 한태영, Bae Youin, Choi Sun Young, Cho Sang Hyun, Han Ju Hee, Kim Hye One, Lee Ji Hyun, Lee Yang Won, Woo Yu Ri대한피부과학회 · Annals of Dermatology2025 · 제37권 제4호대한 소아알레르기 호흡기학회 소아청소년 아토피피부염 진료지침: 2편. 전신 치료 및 최신 치료와 보조요법이 은, 대한 소아알레르기 호흡기학회 진료지침위원회, 김경훈, 김민지, 김종덕, 김환수, 민택기, 박영아, 서동인, 설인숙, 양현종, 우성일, 이용주, 장광천, 전유훈, 정민영, 정성수, 황윤하대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2025 · 제13권 제1호

이 간행물의 다른 논문 (32건)

Comparison of Low-Level Laser Therapy versus Ozone Therapy in the Treatment of Oral Lichen PlanusMerve Erisen, Hakki Oguz Kazancioglupp. 485-491Quality of Life Assessment in Korean Patients with Pemphigus김수찬, 성재용, 노미령pp. 492-498Topical Corticosteroid Phobia among Parents of Children with Atopic Eczema in Korea김철우, 이진용, 허영, 김상석pp. 499-506Oxidative Damage and Nuclear Factor Erythroid 2-Related Factor 2 Protein Expression in Normal Skin and Keloid Tissue남두현, 이윤진, 이상한, 조문균, 조현득, 최창용, 권순범, 김철한, 이미우, 남해선pp. 507-516Efficacy and Safety of Hair Removal with a Long-Pulsed Diode Laser Depending on the Spot Size: A Randomized, Evaluators-Blinded, Left-Right Study조성진, 이영주, 김진용, 권오상, 반주희, 고우석pp. 517-522
원문 보기